Cytisine Transdermal Patch Composition for 24-Hour Drug Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cytisine dosage forms for smoking cessation, such as tablets and capsules, require complex dose regimens and frequent oral administration, leading to reduced patient compliance and gastrointestinal adverse effects, while passive transdermal delivery of cytisine faces challenges in achieving sufficient skin permeation and active ingredient utilization.
Innovation Solution
A transdermal therapeutic system (TTS) containing cytisine with a self-adhesive layer structure comprising silicone-based polymers, polyisobutylenes, and a permeation enhancer with a linear backbone and hydroxy group, allowing for 24-hour release of cytisine, suitable for dosing intervals of 24 hours or 1 day, and providing therapeutically effective amounts.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If oral dosage forms (tablets and capsules) are used for cytisine administration, then the drug can be delivered to the systemic circulation, but the patient compliance is reduced due to complex dose regimens and frequent administration requirements
Solution Approach 1:
The patent segments the total daily dose into multiple smaller reservoirs within the transdermal system, each releasing drug at controlled rates. This allows the system to maintain complex dosing regimens (e.g., varying daily doses from 9mg to 1.5mg over 25 days) while presenting a simple single-application interface to the patient, thereby improving compliance without sacrificing dosing precision
Solution Approach 2:
The transdermal patch acts as an intermediary device between the patient and the drug, automatically managing the complex dosing schedule through its multi-reservoir design and controlled release mechanisms. The patch translates the complex dosing regimen into automatic controlled release patterns, eliminating the need for patient intervention and reducing administration errors
2Reliability
If oral dosage forms are used for cytisine administration, then the drug can be delivered, but gastrointestinal adverse effects occur
Solution Approach 1:
The patent replaces the oral administration route (which passes through the gastrointestinal tract) with a transdermal delivery system. This substitutes the mechanical/digestive process with a direct transdermal penetration mechanism, delivering the drug systemically while completely avoiding gastrointestinal exposure and associated adverse effects
3Ease of operation
If passive transdermal delivery is used for cytisine, then the administration frequency can be reduced, but sufficient skin permeation and active ingredient utilization are challenging
Solution Approach 1:
The patent employs permeation enhancers that chemically or physically modify the skin barrier properties temporarily, and uses controlled release mechanisms that maintain optimal drug concentration gradients across the skin. These parameter changes enable sufficient permeation of cytisine through the skin at extended dosing intervals, achieving both reduced administration frequency and reliable drug delivery
4Loss of time
If transdermal therapeutic system is designed for 24-hour release, then the dosing interval can be extended to 24 hours, but the patch size must be controlled to not more than 50 cm²
Solution Approach 1:
The patent uses composite materials in the patch construction, including multiple polymer matrices with different drug loading capacities and release characteristics, combined with permeation enhancers and controlled release membranes. This composite structure enables high drug delivery efficiency from a compact 50 cm² or smaller area, supporting 24-hour dosing intervals without requiring large patch sizes
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The TTS ensures convenient, prolonged release of cytisine with high active ingredient utilization, reducing the frequency of administration and minimizing adverse effects, thus enhancing patient compliance and comfort.
Implementation Method 1
a permeation enhancer comprising an organic compound having a linear backbone including 6 to 14 carbon atoms and provided with 1 hydroxy group
Implementation Method 2
a polymer selected from the group consisting of silicone-based polymers and polyisobutylenes
Data Source
Figure 1a~1b
Figure 2a~2b
Figure 3a~3b
AI summary
The present invention relates to a transdermal therapeutic system (TTS) for the transdermal administration of cytisine comprising a self-adhesive layer structure containing a therapeutically effective amount of cytisine, such cytisine TTS for use in a method of treatment as well as processes for manufacturing such cytisine TTS.